Copy to clipboard 
TYBR Health announced a $30 million Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The company will use the funds to expand commercial access to its FDA-cleared B3 GEL System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery.
B3 GEL supports post-operative tendon mobility through an intuitive and precise proprietary delivery system, empowering surgeons to achieve superior functional outcomes with seamless integration into existing surgical workflows.
The B3 GEL System is a flowable extracellular matrix hydrogel, cleared by the FDA, designed to protect tendons, ligaments, muscles, and the surrounding soft tissue while they heal.
Since launch, the B3 GEL System has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures. Early adoption has come from surgeons looking for a straightforward way to manage and protect healing tissue without adding time or complexity to the case.
As part of the financing, Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the TYBR Health Board of Directors, alongside independent director Aaron Smith.
“Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals. That part of the equation has gone largely unaddressed,” said Tim Keane, PhD, co-founder and CEO of TYBR Health. “We built TYBR Health around a simple principle: managing the healing environment should complement good surgical technique and contribute to better recovery for patients.”
Source: TYBR Health
TYBR Health announced a $30 million Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The company will use the funds to expand commercial access to its FDA-cleared B3 GEL System, broaden its product indications, and run clinical studies evaluating tissue...
TYBR Health announced a $30 million Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The company will use the funds to expand commercial access to its FDA-cleared B3 GEL System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery.
B3 GEL supports post-operative tendon mobility through an intuitive and precise proprietary delivery system, empowering surgeons to achieve superior functional outcomes with seamless integration into existing surgical workflows.
The B3 GEL System is a flowable extracellular matrix hydrogel, cleared by the FDA, designed to protect tendons, ligaments, muscles, and the surrounding soft tissue while they heal.
Since launch, the B3 GEL System has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures. Early adoption has come from surgeons looking for a straightforward way to manage and protect healing tissue without adding time or complexity to the case.
As part of the financing, Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the TYBR Health Board of Directors, alongside independent director Aaron Smith.
“Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals. That part of the equation has gone largely unaddressed,” said Tim Keane, PhD, co-founder and CEO of TYBR Health. “We built TYBR Health around a simple principle: managing the healing environment should complement good surgical technique and contribute to better recovery for patients.”
Source: TYBR Health
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
PM
Patrick McGuire is an ORTHOWORLD Contributor.
